4.3 Review

A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis

期刊

MULTIPLE SCLEROSIS JOURNAL
卷 21, 期 3, 页码 318-331

出版社

SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458514564485

关键词

Multiple sclerosis; comorbidity; cardiac; stroke; peripheral vascular disease; incidence; prevalence; systematic review

资金

  1. National Multiple Sclerosis Society
  2. MS Society of Canada

向作者/读者索取更多资源

Background: Findings regarding the prevalence of vascular comorbidities in multiple sclerosis (MS) are conflicting. Objective: The objective of this review is to estimate the incidence and prevalence of vascular comorbidities and predisposing comorbidities in persons with MS and to assess the quality of the included studies. Methods: The PubMed, EMBASE, SCOPUS and Web of Knowledge databases, conference proceedings, and reference lists of retrieved articles were searched. One reviewer abstracted data using a standardized data collection form, while the second reviewer verified the abstraction. Included studies were assessed qualitatively. Quantitatively, we assessed studies using the I-2 statistic, and conducted meta-analyses for population-based studies only. Results: The prevalence of hypertension and hyperlipidemia exceeded 10% in the MS population and increased with age. While the prevalence of ischemic heart disease, congestive heart failure, and stroke were less than 5% overall, the prevalence of these conditions exceeded expectations when compared to the general population. Cardiac valvular disease, however, affected the MS population less often than expected. Problems with study quality were common. Conclusion: Despite the relatively high prevalence of some vascular comorbidities in the MS population, important gaps exist in our understanding of their epidemiology. Most of our knowledge is based on studies conducted in a small number of regions.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Editorial Material Clinical Neurology

Imposter clinical trials or answering questions with observational data

Gary Cutter

MULTIPLE SCLEROSIS JOURNAL (2023)

Article Clinical Neurology

The impact of relapse definition and measures of durability on MS clinical trial outcomes

Sammita Satyanarayan, Gary Cutter, Stephen Krieger, Stacey Cofield, Jerry S. Wolinsky, Fred Lublin

Summary: The stringency of relapse definition affects measurements of relapse rate and composite endpoints in RRMS. Even with the most inclusive relapse definition, 43% of patients did not have durable worsening in the clinical trial. Therefore, relapse definition and durability should be considered in RRMS research to avoid overestimating disease progression.

MULTIPLE SCLEROSIS JOURNAL (2023)

Article Clinical Neurology

Primary results of a phase-III, randomized controlled trial of the Behavioral Intervention for increasing Physical Activity in Multiple Sclerosis project

Robert W. Motl, Ariel Kidwell-Chandler, Brian M. Sandroff, Lara A. Pilutti, Gary R. Cutter, Roberto Aldunate, Rachel E. Bollaert

Summary: A randomized controlled trial was conducted to examine the effectiveness of an Internet-based behavioral intervention on increasing physical activity in persons with multiple sclerosis (MS). The study found that the intervention led to immediate and sustained increases in moderate-to-vigorous physical activity among participants. This study provides evidence for a scalable approach to promote physical activity in persons with MS.

MULTIPLE SCLEROSIS JOURNAL (2023)

Article Clinical Neurology

Clinical course of multiple sclerosis and patient experiences during breast cancer treatment

Alyssa N. Nylander, Jessica Singh, Shane Poole, Annika Anderson, Ruth Ann Marrie, Hope Rugo, Riley Bove

Summary: In this study, a case series of multiple sclerosis (MS) patients diagnosed with breast cancer was analyzed retrospectively to understand the clinical characteristics and treatment strategies. The study found that the relapse rate of MS during breast cancer treatment was low, and the neurologic function scores of the patients remained stable. This study provides valuable information for understanding the clinical management of patients with concurrent MS and breast cancer.

MULTIPLE SCLEROSIS JOURNAL (2023)

Article Clinical Neurology

The Barancik lecture: Comorbidity in multiple sclerosis-Looking backward, looking forward

Ruth Ann Marrie

Summary: Comorbidity is common in people with multiple sclerosis (MS) and has significant impacts on outcomes such as relapses, disability progression, quality of life, healthcare use, and mortality. It is important to prevent and treat comorbidity effectively in people with MS by evaluating comorbidity, understanding its management in the context of MS, testing interventions tailored to MS patients, and determining optimal care models for comorbidity management.

MULTIPLE SCLEROSIS JOURNAL (2023)

Article Clinical Neurology

Management of vascular risk in people with multiple sclerosis at the time of diagnosis in England: A population-based study

Raffaele Palladino, Ruth Ann Marrie, Azeem Majeed, Jeremy Chataway

Summary: This study investigates the prevalence of diabetes and hypertension, as well as the usage of antidiabetic, antihypertensive, and lipid-lowering medications in people with multiple sclerosis (PwMS) at the time of diagnosis. The results show that PwMS have higher prevalence of diabetes and hypertension, but lower usage of corresponding medications. It is suggested that clinical guidelines should be developed to improve vascular management in PwMS.

MULTIPLE SCLEROSIS JOURNAL (2023)

Article Clinical Neurology

Incidence and prevalence of paediatric-onset multiple sclerosis in two Canadian provinces: a population-based study representing over half of Canada's population

Fardowsa L. A. Yusuf, Ayesha Asaf, Ruth Ann Marrie, Ping Li, Kyla McKay, Yinshan Zhao, Feng Zhu, Colleen Maxwell, Helen Tremlett

Summary: Canada has one of the highest rates of paediatric-onset multiple sclerosis (PoMS) globally, and the prevalence, but not incidence, has increased over time. Allocation of resources to support the growing youth population with MS should be a priority.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Article Urology & Nephrology

Effects of a More Selective Arteriovenous Fistula Strategy on Vascular Access Outcomes

Michael Allon, Alian Al-Balas, Carlton J. Young, Gary R. Cutter, Timmy Lee

Summary: This study compared two strategies for the choice of initial vascular access in hemodialysis patients. The results showed that a more selective approach to arteriovenous fistula (AVF) placement can reduce the frequency of vascular access procedures and the cost of access management.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2023)

Article Clinical Neurology

Within-person fluctuations over three years in depression, anxiety, fatigue, and health-related quality of life in multiple sclerosis

Ruth Ann Marrie, Charles N. Bernstein, Casandra Dolovich, James M. Bolton, Lesley A. Graff, Carol A. Hitchon, Lisa M. Lix, James J. Marriott, John D. Fisk

Summary: This study aimed to assess the association between health-related quality of life (HRQoL) and depression, anxiety, fatigue, cognition, physical functioning, and physical comorbidities in multiple sclerosis (MS) patients. The results showed that increases in depression and fatigue were associated with decreases in physical HRQoL, while increases in depression, anxiety, and comorbidity count were associated with decreases in mental HRQoL.

MULTIPLE SCLEROSIS JOURNAL (2023)

Article Clinical Neurology

Do the current MS clinical course descriptors need to change and if so how? A survey of the MS community

Alan J. Thompson, Marcello Moccia, Maria Pia Amato, Peter A. Calabresi, Marcia Finlayson, Annie Hawton, Fred D. Lublin, Ruth Ann Marrie, Xavier Montalban, Michael Panzara, Maria Pia Sormani, Jon Strum, Barbara G. Vickrey, Timothy Coetzee

Summary: The survey results show that stakeholders of multiple sclerosis (MS) believe that the current clinical course descriptors need to change and support a mechanism-driven framework for describing MS. Clinical validation and ease of communication with patients are the most important considerations when developing a new framework.

MULTIPLE SCLEROSIS JOURNAL (2023)

Review Clinical Neurology

Enhancing involvement of people with multiple sclerosis in clinical trial design

Emma Gray, Anneesa Amjad, Jenny Robertson, Judy Beveridge, Susan Scott, Guy Peryer, Marie Braisher, Cheryl Pugh, Sara Peres, Ruth Ann Marrie, Maria Pia Sormani, Jeremy Chataway

Summary: A rapid review on patient and public involvement (PPI) in multiple sclerosis (MS) clinical trials over the past 5 years revealed that only 8 trials mentioned PPI, mostly due to funding requirements. The OCTOPUS trial, an example of PPI in progressive MS, involved individuals affected by MS in governance and decision-making processes, resulting in a more accessible and inclusive trial design. Enhancing PPI in future MS clinical trials is crucial for improving study quality and relevance.

MULTIPLE SCLEROSIS JOURNAL (2023)

Review Clinical Neurology

Enhancing diversity of clinical trial populations in multiple sclerosis

Ruth Ann Marrie, Jeremy Chataway, Barbara E. Bierer, Marcia Finlayson, Elena H. Martinez-Lapiscina, Jennifer Panagoulias, Maria Pia Sormani, Mitzi Joi Williams, Lilyana Amezcua

Summary: This article summarizes recommendations for enhancing diversity and inclusion in clinical trials for multiple sclerosis (MS), including the use of diversity plans, community engagement and education, cultural competency training, adaptive designs, and reducing participant burden.

MULTIPLE SCLEROSIS JOURNAL (2023)

Review Clinical Neurology

Assessing heterogeneity of treatment effect in multiple sclerosis trials

Maria Pia Sormani, Jeremy Chataway, David M. Kent, Ruth Ann Marrie

Summary: Multiple sclerosis (MS) has varied outcomes, and evaluating heterogeneity of treatment effect (HTE) is important. Various statistical techniques can assess HTE, with multivariable predictive approaches offering more patient-centered results. This review examines methods used to estimate HTE in MS clinical trials.

MULTIPLE SCLEROSIS JOURNAL (2023)

Review Clinical Neurology

Improving the efficiency of clinical trials in multiple sclerosis

Ruth Ann Marrie, Maria Pia Sormani, Sean Apap Mangion, Francesca Bovis, Winson Y. Cheung, Gary R. Cutter, Peter Feys, Michael D. Hill, Marcus Werner Koch, Morgan McCreary, Ellen M. Mowry, Jay J. H. Park, Fredrik Piehl, Amber Salter, Jeremy Chataway

Summary: The current designs for clinical trials treating progressive multiple sclerosis (MS) have limitations and have not been successful. This paper discusses complex innovative trial designs and intermediate and composite outcomes to improve trial design efficiency in MS. Recommendations include increasing the use of complex innovative designs, developing biomarkers to enrich trial populations, prioritizing intermediate outcomes targeting therapeutic mechanisms, and investigating data linkage for long-term outcomes. Novel trial designs and further development of intermediate outcomes may improve clinical trial efficiency and address novel therapeutic questions in MS.

MULTIPLE SCLEROSIS JOURNAL (2023)

暂无数据